For 40 years, healthcare providers like you have used Cloderm Cream to provide efficacy with tolerability when treating corticosteroid-responsive dermatoses ¹,²

Learn how Cloderm Cream can help your patients

Results You Can See*

Proven efficacy for treatment of corticosteroid-responsive dermatoses²

Results of a double-blind, simultaneous, symmetric, paired-comparison clinical trial (left side versus right side) involving patients (n=100) with eczema/atopic dermatitis evaluating the efficacy and safety of clocortolone pivalate 0.1% versus a placebo cream base.²

*Objective criteria included decrease of erythema, edema, transudation and, if present, vesicles or bullae, papules, plaques, scaling, crusting, fissures, and lichenification.

Epidermal Impact

A medium-potency topical in a specifically formulated cream¹

Designed to be Different

Cloderm Cream is formulated to enhance lipid solubility

Structural modifications (shown in teal) are associated with:
  • Increased anti-inflammatory activity3,6
  • Reduced mineralocorticoid activity and allergenicity6
  • Enhanced percutaneous absorption3,6

Established Safety Profile

A well-tolerated mid-potent corticosteroid

  • No age restrictions on use. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings1
  • No age restrictions on use. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings1
  • Cloderm Cream is applicable on most areas of the body. Instruct patients to avoid contact with the eyes and mouth1
  • Clocortolone pivalate is a corticosteroid in allergy Group C, a group that exhibits the lowest potential risk for allergic contact dermatitis induced by a topically applied corticosteroid7
  • No systemic, cumulative, or delayed adverse events related to study drug were observed during treatment up to 7 months8

Not an actual patient.

Does Jessica remind you of any of your patients?

  • 26-year-old actress with no previous history of corticosteroid-responsive dermatoses
  • Recently started using a new cleanser on her face and body; 10 days later she began to develop a rash on her cheeks, neck, and arms
  • Complains about rash stinging and burning, and her skin feeling dry
  • Prescribed hydrocortisone and told to discontinue using her new cleanser
  • Before her next appointment, Jessica reported that her rash had not improved

For your patients like Jessica, consider Cloderm Cream

  • Cloderm Cream can be safely used on the face
  • Formulation is lanolin-free and does not contain propylene glycol or added fragrance
  • Has been shown to improve symptoms in as little as 4 days²
  • $0 co-pay for eligible patients*

*Limitations apply. For insured and uninsured eligible patients. See co-pay card for details.

Not an actual patient

Savings for Eligible Patients

There is more you can do with Cloderm Cream

Sign up today to receive more information about Cloderm Cream.
You can also download the Cloderm Cream Co-Pay Card and the Sample Request Form.

INDICATION AND IMPORTANT SAFETY INFORMATION

Cloderm Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with Cloderm Cream include burning, itching, irritation, dryness, and folliculitis. Cloderm Cream is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

You are encouraged to report negative side effects of prescription drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/Safety/MedWatch

Please see Full Prescribing Information.

References: 1. Cloderm [package insert]. Princeton, NJ: Promius Pharma, LLC; 2017. 2. Rosenthal AL. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980;25(1):96-98. 3. Del Rosso JQ, Kircik L. A comprehensive review of clocortolone pivalate 0.1% cream: structural development, formulation characteristics, and studies supporting treatment of corticosteroid-responsive dermatoses. J Clin Aesthet Dermatol. 2012;5(7):20-24. 4. Kircik LH. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol. 2014;13(5):582-585. 5. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5(2):125-130. 6. Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development—a process of ‘‘planned serendipity.’’ J Pharm Sci. 2008;97(8):2936-2947. 7. Jacob SE, Steele T. Corticosteroid classes: A quick reference guide including patch test substances and cross-reactivity. J Am Acad Dermatol. 2006;54(4):723-727. 8. Niermann MM. Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis. Cutis. 1981;27(6):670-671. 9. Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs Dermatol. 2012;11(10):1194-1198.

INDICATION AND IMPORTANT SAFETY INFORMATION
Cloderm Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The most common adverse events with Cloderm Cream include burning, itching, irritation, dryness, and folliculitis. Cloderm Cream is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.
IMPORTANT PATIENT SAFETY INFORMATION
  • Cloderm Cream is for external use only. Avoid contact with the eyes.
  • Do not bandage or wrap the treated area unless directed by your healthcare provider.
  • Pediatric patients: if using Cloderm Cream in the diaper area of a young child, please contact your healthcare provider before putting a tight-fitting diaper or plastic pants on the child as this may act like a bandage or wrap.
  • Do not use Cloderm Cream if you are allergic to any of the ingredients in Cloderm Cream.